Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?
Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?
复制标题
DOI：
10.1016/j.pharmthera.2020.107703
复制
发表时间：
2021-03
影响因子：
13.5
通讯作者：
Seubert JM
中科院分区：
文献类型：
--
作者：
Darwesh AM;Bassiouni W;Sosnowski DK;Seubert JM
由严重急性呼吸系统综合征冠状病毒2 （SARS-CoV-2）引起的2019冠状病毒病（COVID-19）目前已导致全球大流行，全球已有数百万确诊病例，而且病例还在增加。新型SARS-CoV-2不仅影响肺部，引起严重的急性呼吸功能障碍，还会导致包括心血管系统在内的多个器官和生理系统出现明显功能障碍。大量研究表明，病毒感染会引发过度的免疫反应、高凝血和氧化应激，这是导致COVID-19患者心血管疾病预后不良的重要原因。迄今为止，还没有批准的COVID-19疫苗或疗法。因此，心血管保护和支持治疗对COVID-19患者的整体预后至关重要。越来越多的文献已经证明了n-3多不饱和脂肪酸（n-3 PUFA）对心血管系统的有益作用，包括改善不受控制的炎症反应，减少氧化应激和减轻凝血功能。此外，已经证明n-3 PUFAs，二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）是一组有效的生物活性脂质介质的前体，内源性产生，介导许多归因于其母体化合物的有益作用。考虑到n-3 PUFAs及其代谢物良好的安全性，将n-3 PUFAs作为COVID-19患者临床管理的潜在辅助疗法是合理的。在本文中，我们概述了COVID-19继发心血管并发症的发病机制，并重点讨论了n-3 PUFAs及其代谢物可能带来益处的机制。
Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has currently led to a global pandemic with millions of confirmed and increasing cases around the world. The novel SARS-CoV-2 not only affects the lungs causing severe acute respiratory dysfunction but also leads to significant dysfunction in multiple organs and physiological systems including the cardiovascular system. A plethora of studies have shown the viral infection triggers an exaggerated immune response, hypercoagulation and oxidative stress, which contribute significantly to poor cardiovascular outcomes observed in COVID-19 patients. To date, there are no approved vaccines or therapies for COVID-19. Accordingly, cardiovascular protective and supportive therapies are urgent and necessary to the overall prognosis of COVID-19 patients. Accumulating literature has demonstrated the beneficial effects of n-3 polyunsaturated fatty acids (n-3 PUFA) toward the cardiovascular system, which include ameliorating uncontrolled inflammatory reactions, reduced oxidative stress and mitigating coagulopathy. Moreover, it has been demonstrated the n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms that may contribute to the likely benefits of n-3 PUFAs and their metabolites.
影响因子：
9.1
作者：
Liu, Yingxia;Yang, Yang;Liu, Lei
通讯作者：
Liu, Lei